Literature DB >> 8807064

Identification for mar mutants among quinolone-resistant clinical isolates of Escherichia coli.

K Maneewannakul1, S B Levy.   

Abstract

Quinolone-resistant clinical Escherichia coli isolates were examined for mutations in the marRAB operon of the multiple antibiotic resistance (mar) locus. Among 23 strains evaluated, 8 were chosen for further study: 3 that showed relatively high levels of uninduced, i.e., constitutive, expression of the operon and 5 with variable responses to induction by salicylate or tetracyclines. The marR genes, specifying the repressor of the operon, cloned from the three strains constitutively expressing the operon did not reduce the level of expression of beta-galactosidase from a marO::lacZ transcriptional fusion and were therefore mutant; however, marR genes cloned from the five other clinical strains repressed LacZ expression and were wild type. All three mutant marR genes contained more than one mutation: a deletion and a point mutation. Inactivation of the mar locus in the three known marR mutant strains with a kanamycin resistance cassette introduced by homologous recombination reduced resistance to quinolones and multiple antibiotics. These findings indicate that mar operon mutations exist in quinolone-resistant clinical E. coli isolates and contribute to quinolone and multidrug resistance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807064      PMCID: PMC163397     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Prevalence of fluoroquinolone-resistant bacterial isolates in four medical centers during the first quarter of 1990.

Authors:  A L Barry; P C Fuchs; M A Pfaller; S D Allen; E H Gerlach
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-12       Impact factor: 3.267

2.  gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli.

Authors:  S Nakamura; M Nakamura; T Kojima; H Yoshida
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

3.  Norfloxacin resistance in a clinical isolate of Escherichia coli.

Authors:  H Aoyama; K Sato; T Kato; K Hirai; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

4.  New method for generating deletions and gene replacements in Escherichia coli.

Authors:  C M Hamilton; M Aldea; B K Washburn; P Babitzke; S R Kushner
Journal:  J Bacteriol       Date:  1989-09       Impact factor: 3.490

5.  marA locus causes decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.

Authors:  S P Cohen; L M McMurry; S B Levy
Journal:  J Bacteriol       Date:  1988-12       Impact factor: 3.490

6.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

7.  Multiple antibiotic resistance (mar) locus protects Escherichia coli from rapid cell killing by fluoroquinolones.

Authors:  J D Goldman; D G White; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

8.  Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction.

Authors:  S P Cohen; L M McMurry; D C Hooper; J S Wolfson; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

9.  A rapid chemical procedure for isolation and purification of chromosomal DNA from gram-negative bacilli.

Authors:  A Beji; D Izard; F Gavini; H Leclerc; M Leseine-Delstanche; J Krembel
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

10.  Amplifiable resistance to tetracycline, chloramphenicol, and other antibiotics in Escherichia coli: involvement of a non-plasmid-determined efflux of tetracycline.

Authors:  A M George; S B Levy
Journal:  J Bacteriol       Date:  1983-08       Impact factor: 3.490

View more
  59 in total

1.  High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA.

Authors:  A Mazzariol; Y Tokue; T M Kanegawa; G Cornaglia; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 2.  Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

3.  Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli.

Authors:  S Bagel; V Hüllen; B Wiedemann; P Heisig
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

4.  Prediction of resistance development against drug combinations by collateral responses to component drugs.

Authors:  Christian Munck; Heidi K Gumpert; Annika I Nilsson Wallin; Harris H Wang; Morten O A Sommer
Journal:  Sci Transl Med       Date:  2014-11-12       Impact factor: 17.956

5.  Risk factors for fecal quinolone-resistant Escherichia coli in Mexican children.

Authors:  Mussaret B Zaidi; Emma Zamora; Pilar Diaz; Linda Tollefson; Paula J Fedorka-Cray; Marcia L Headrick
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

6.  The periplasmic protein MppA requires an additional mutated locus to repress marA expression in Escherichia coli.

Authors:  Xiaowen Bina; Vincent Perreten; Stuart B Levy
Journal:  J Bacteriol       Date:  2003-02       Impact factor: 3.490

Review 7.  Potential impact of increased use of biocides in consumer products on prevalence of antibiotic resistance.

Authors:  Peter Gilbert; Andrew J McBain
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

8.  Aromatic acid metabolites of Escherichia coli K-12 can induce the marRAB operon.

Authors:  Lon M Chubiz; Christopher V Rao
Journal:  J Bacteriol       Date:  2010-07-16       Impact factor: 3.490

9.  A Hybrid Drug Limits Resistance by Evading the Action of the Multiple Antibiotic Resistance Pathway.

Authors:  Kathy K Wang; Laura K Stone; Tami D Lieberman; Michal Shavit; Timor Baasov; Roy Kishony
Journal:  Mol Biol Evol       Date:  2015-11-03       Impact factor: 16.240

10.  Role of the acrAB locus in organic solvent tolerance mediated by expression of marA, soxS, or robA in Escherichia coli.

Authors:  D G White; J D Goldman; B Demple; S B Levy
Journal:  J Bacteriol       Date:  1997-10       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.